Comparison and monitoring of antibody response in convalescent and healthy vaccinated individuals against RBD and PCS of SARS-CoV-2 spike protein

References

• Almuqrin, A., Davidson, A. D., Williamson, M. K., Lewis, P. A., Heesom, K. J., Morris, S., Gilbert, S. C., & Matthews, D. A. (2021). SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription. Genome Medicine, 13(1), 43. https://doi.org/10.1186/s13073-021-00859-1
   PubMed Web of Science ®Google Scholar
• Altawalah, H. (2021). Antibody responses to natural SARS-CoV-2 infection or after COVID-19 vaccination. Vaccines, 9(8), 910. https://doi.org/10.3390/vaccines9080910
   Web of Science ®Google Scholar
• Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., Qu, Y., Li, F., Lv, Q., Wang, W., Xue, J., Gong, S., Liu, M., Wang, G., Wang, S., … Qin, C. (2020). The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature, 583(7818), 830–833. https://doi.org/10.1038/s41586-020-2312-y
   PubMed Web of Science ®Google Scholar
• Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., Schultze-Florey, C., Ravens, I., Willenzon, S., Bubke, A., Ristenpart, J., Janssen, A., Ssebyatika, G., Bernhardt, G., Münch, J., … Behrens, G. M. N. (2021). Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature Medicine, 27(9), 1525–1529. https://doi.org/10.1038/s41591-021-01449-9
   PubMed Web of Science ®Google Scholar
• Boechat, J. L., Chora, I., Morais, A., & Delgado, L. (2021). The immune response to SARS-CoV-2 and COVID-19 immunopathology–current perspectives. Pulmonology, 27(5), 423–437. https://doi.org/10.1016/j.pulmoe.2021.03.008
   PubMed Web of Science ®Google Scholar
• Chung, H., Noh, J. Y., Koo, B.-S., Hong, J. J., & Kim, H. K. (2022). SARS-CoV-2 mutations acquired during serial passage in human cell lines are consistent with several of those found in recent natural SARS-CoV-2 variants. Computational and Structural Biotechnology Journal. 20, 1925–1934. https://doi.org/10.1016/j.csbj.2022.04.022
   PubMed Web of Science ®Google Scholar
• Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N. G., & Decroly, E. (2020). The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Research, 176, 104742. https://doi.org/10.1016/j.antiviral.2020.104742
   PubMed Web of Science ®Google Scholar
• Dwyer, C. J., Cloud, C. A., Wang, C., Heidt, P., Chakraborty, P., Duke, T. F., McGue, S., Jeffcoat, B., Dunne, J., Johnson, L., Choi, S., Nahhas, G. J., Gandy, A. S., Babic, N., Nolte, F. S., Howe, P., Ogretmen, B., Gangaraju, V. K., Tomlinson, S., … Mehrotra, S. (2021). Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. Iscience, 24(6), 102489. https://doi.org/10.1016/j.isci.2021.102489
   PubMed Web of Science ®Google Scholar
• Eyre, D. W., Lumley, S. F., Wei, J., Cox, S., James, T., Justice, A., Jesuthasan, G., O'Donnell, D., Howarth, A., Hatch, S. B., Marsden, B. D., Jones, E. Y., Stuart, D. I., Ebner, D., Hoosdally, S., Crook, D. W., Peto, T. E., Walker, T. M., Stoesser, N. E., … Jeffery, K. (2021). Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status. Clin Microbiol Infect, 27(10), 1516.e7–1516.e14. https://doi.org/10.1016/j.cmi.2021.05.041
   PubMed Web of Science ®Google Scholar
• Feng, C., Shi, J., Fan, Q., Wang, Y., Huang, H., Chen, F., Tang, G., Li, Y., Li, P., Li, J., Cui, J., Guo, L., Chen, S., Jiang, M., Feng, L., Chen, L., Lei, C., Ke, C., Deng, X., … Li, F. (2021). Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery. Nature Communications, 12(1), 4984. https://doi.org/10.1038/s41467-021-25312-0
   Web of Science ®Google Scholar
• Feuillet, V., Canard, B., & Trautmann, A. (2021). Combining antivirals and immunomodulators to fight COVID-19. Trends in Immunology, 42(1), 31–44. https://doi.org/10.1016/j.it.2020.11.003
   PubMed Web of Science ®Google Scholar
• Funk, C. D., Laferrière, C., & Ardakani, A. (2020). A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Frontiers in Pharmacology, 11, 937. https://doi.org/10.3389/fphar.2020.00937
   Web of Science ®Google Scholar
• Gobbi, F., Buonfrate, D., Moro, L., Rodari, P., Piubelli, C., Caldrer, S., Riccetti, S., Sinigaglia, A., & Barzon, L. (2021). Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection. Viruses, 13(3), 422. https://doi.org/10.3390/v13030422
   PubMed Web of Science ®Google Scholar
• Guo, Y. R., Cao, Q. D., Hong, Z. S., Tan, Y. Y., Chen, S. D., Jin, H. J., Tan K.-S., Wang D.-Y., & Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Military Medical Research, 7, 1–10. https://doi.org/10.1186/s40779-020-00240-0
   PubMed Web of Science ®Google Scholar
• Harrison, A. G., Lin, T., & Wang, P. (2020). Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends in Immunology, 41(12), 1100–1115. https://doi.org/10.1016/j.it.2020.10.004
   PubMed Web of Science ®Google Scholar
• Hedges, J. F., Thompson, M. A., Snyder, D. T., Robison, A., Taylor, M. P., & Jutila, M. A. (2021). Titers, prevalence, and duration of SARS-CoV-2 antibodies in a local COVID-19 outbreak and following vaccination. Vaccines, 9(6), 587. https://doi.org/10.3390/vaccines9060587
   Web of Science ®Google Scholar
• Heidari-Japelaghi, R., Haddad, R., Valizadeh, M., Dorani-Uliaie, E., & Jalali-Javaran, M. (2019). Elastin-like polypeptide fusions for high-level expression and purification of human IFN-γ in Escherichia coli. Analytical Biochemistry, 585, 113401. https://doi.org/10.1016/j.ab.2019.113401
   PubMed Web of Science ®Google Scholar
• Johnson, M. C., Lyddon, T. D., Suarez, R., Salcedo, B., LePique, M., Graham, M., Ricana, C., Robinson, C., & Ritter, D. G. (2020). Optimized pseudotyping conditions for the SARS-COV-2 spike glycoprotein. Journal of Virology, 94(21), e01062-20. https://doi.org/10.1128/JVI.01062-20
   Web of Science ®Google Scholar
• Khakdan, F., Alizadeh, H., & Ranjbar, M. (2018). Molecular cloning, functional characterization and expression of a drought inducible phenylalanine ammonia-lyase gene (ObPAL) from Ocimum basilicum L. Plant Physiology and Biochemistry. 130, 464–472. https://doi.org/10.1016/j.plaphy.2018.07.026
   PubMed Web of Science ®Google Scholar
• Klumpp-Thomas, C., Kalish, H., Drew, M., Hunsberger, S., Snead, K., Fay, M. P., Mehalko, J., Shunmugavel, A., Wall, V., Frank, P., Denson, J.-P., Hong, M., Gulten, G., Messing, S., Hicks, J., Michael, S., Gillette, W., Hall, M. D., Memoli, M. J., Esposito, D., & Sadtler, K. (2021). Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling. Nature Communications, 12(1), 113. https://doi.org/10.1038/s41467-020-20383-x
   PubMed Web of Science ®Google Scholar
• Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B., & Prado, E. O. (2021). SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. Npj Vaccines. 6(1), 28. https://doi.org/10.1038/s41541-021-00292-w
   PubMed Web of Science ®Google Scholar
• Lange, A., Borowik, A., Bocheńska, J., Rossowska, J., & Jaskuła, E. (2021). Immune response to COVID-19 mRNA vaccine—A pilot study. Vaccines, 9(5), 488. https://doi.org/10.3390/vaccines9050488
   Web of Science ®Google Scholar
• Li, Y., Ma, M-l., Lei, Q., Wang, F., Hong, W., Lai, D-y., Hou, H., Xu, Z-w., Zhang, B., Chen, H., Yu, C., Xue, J-b., Zheng, Y-x., Wang, X-n., Jiang, H-w., Zhang, H-n., Qi, H., Guo, S-j., Zhang, Y., … Tao, S-c (2021). Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. Cell Reports, 34(13), 108915. https://doi.org/10.1016/j.celrep.2021.108915
   PubMed Web of Science ®Google Scholar
• Liu, Y.-M., Lee, Y.-L., Liu, C.-E., Chen, Y.-C., Tien, N., & Su, W.-C. (2022). Neutralization of SARS-CoV-2 Omicron BA. 1, BA. 4, and BA. 5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination. Infection, 15, 1-4. https://doi.org/10.1007/s15010-022-01922-8
   Google Scholar
• Mendonça, S. A., Lorincz, R., Boucher, P., & Curiel, D. T. (2021). Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. Npj Vaccines, 6(1), 97. https://doi.org/10.1016/B978-0-323-90248-9.00003-6
   PubMed Web of Science ®Google Scholar
• Mohammadzadeh Hosseini Moghri, S. A. H., Kiadeh, S. G. H., & Rahaiee, S. (2021). In silico investigation of lysostaphin-producing novel strains as an enzybiotic against methicillin-resistant Staphylococcus aureus. Informatics in Medicine Unlocked, 24, 100623. https://doi.org/10.1016/j.imu.2021.100623
   Google Scholar
• Mohammadzadeh Hosseini Moghri, S. A. H., Ranjbar, M., Hassannia, H., & Khakdan, F. (2021). Designing a novel multi-epitope vaccine against SARS-CoV-2; Implication for viral binds and fusion inhibition through inducing neutralizing antibodies. BioRxiv, 2021-06. https://doi.org/10.1101/2021.06.16.448772
   Google Scholar
• Mohammadzadeh Hosseini Moghri, S. A. H., Mahmoodi Chalbatani, G., Ranjbar, M., Raposo, C., & Abbasian, A. (2022). CD171 Multi-epitope peptide design based on immuno-informatics approach as a cancer vaccine candidate for glioblastoma. Journal of Biomolecular Structure and Dynamics, 41(3), 1028–1040. https://doi.org/10.1080/07391102.2021.2020166
   PubMed Web of Science ®Google Scholar
• Mohammadzadeh Hosseini Moghri, S. A. H., Ranjbar, M., Hassannia, H., & Khakdan, F. (2022). In silico analysis of the conserved surface-exposed epitopes to design novel multiepitope peptide vaccine for all variants of the SARS-CoV-2. Journal of Biomolecular Structure and Dynamics, 1–13. https://doi.org/10.1080/07391102.2022.2123395
   Web of Science ®Google Scholar
• Mulinari Turin de Oliveira, N., Fernandes da Silva Figueiredo, I., Cristine Malaquias da Silva, L., Sauruk da Silva, K., Regis Bueno, L., Barbosa da Luz, B., Rita Corso, C., Paula Werner, M. F., Soares Fernandes, E., & Maria-Ferreira, D. (2020). Tissue proteases and immune responses: Influencing factors of COVID-19 severity and mortality. Pathogens, 9(10), 817. https://doi.org/10.3390/pathogens9100817
   PubMed Web of Science ®Google Scholar
• Ni, L., Ye, F., Cheng, M.-L., Feng, Y., Deng, Y.-Q., Zhao, H., Wei, P., Ge, J., Gou, M., Li, X., Sun, L., Cao, T., Wang, P., Zhou, C., Zhang, R., Liang, P., Guo, H., Wang, X., Qin, C.-F., Chen, F., & Dong, C. (2020). Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity, 52(6), 971–977.e3. https://doi.org/10.1016/j.immuni.2020.04.023
   PubMed Web of Science ®Google Scholar
• Pinilla, J., Barber, P., Vallejo-Torres, L., Rodríguez-Mireles, S., López-Valcárcel, B. G., & Serra-Majem, L. (2021). The economic impact of the SARS-COV-2 (COVID-19) pandemic in Spain. International Journal of Environmental Research and Public Health, 18(9), 4708. https://doi.org/10.3390/ijerph18094708
   PubMed Web of Science ®Google Scholar
• Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand, S. P., Goyette, G., Benlarbi, M., Ding, S., Medjahed, H., Lewin, A., Perreault, J., Tremblay, T., Gendron-Lepage, G., Gauthier, N., Carrier, M., Marcoux, D., Piché, A., … Finzi, A. (2020). Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike. Cell Reports. Medicine, 1(7), 100126. https://doi.org/10.1016/j.xcrm.2020.100126
   PubMedGoogle Scholar
• Pushparajah, D., Jimenez, S., Wong, S., Alattas, H., Nafissi, N., & Slavcev, R. A. (2021). Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Advanced Drug Delivery Reviews, 170, 113–141. https://doi.org/10.1016/j.addr.2021.01.003
   PubMed Web of Science ®Google Scholar
• Ravichandran, S., Coyle, E. M., Klenow, L., Tang, J., Grubbs, G., Liu, S., Wang, T., Golding, H., & Khurana, S. (2020). Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Science Translational Medicine, 12(550), eabc3539. https://doi.org/10.1126/scitranslmed.abc3539
   Web of Science ®Google Scholar
• Rossi, G. A., Sacco, O., Mancino, E., Cristiani, L., & Midulla, F. (2020). Differences and similarities between SARS-CoV and SARS-CoV-2: Spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases. Infection, 48(5), 665–669. https://doi.org/10.1007/s15010-020-01486-5
   PubMed Web of Science ®Google Scholar
• Sarvestani, R., Latifi, A. M., Alizadeh, H., & Mirzaei, M. (2021). An approach for recombinant epidermal growth factor purification using an elastin-like protein tag. Journal of Applied Biotechnology Reports, 8(2), 127-132. https://doi.org/10.30491/jabr.2020.110243
   Google Scholar
• Stellini, R., Gianello, R., Meloni, A., Croce, E., Materzanini, P., & Gomarasca, W. (2022). Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection. Infection, 50(3), 791–793. https://doi.org/10.1007/s15010-021-01729-z
   PubMed Web of Science ®Google Scholar
• Uengwetwanit, T., Chutiwitoonchai, N., Wichapong, K., & Karoonuthaisiri, N. (2022). Identification of novel SARS-CoV-2 RNA dependent RNA polymerase (RdRp) inhibitors: From in silico screening to experimentally validated inhibitory activity. CSBJ, 20, 882–890. https://doi.org/10.1016/j.csbj.2022.02.001
   Google Scholar
• Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99–111. https://doi.org/10.1016/S0140-6736(20)32661-1
   PubMed Web of Science ®Google Scholar
• Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181(2), 281–292.e6. https://doi.org/10.1016/j.cell.2020.02.058
   PubMed Web of Science ®Google Scholar
• Wang, X., Dhindsa, R., Povysil, G., Zoghbi, A., Motelow, J., Hostyk, J., et al. (2020). Transcriptional inhibition of host viral entry proteins as a therapeutic strategy for SARS-CoV-2. Preprints https://doi.org/10.20944/preprints202003.0360.v1
   Google Scholar
• Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020). Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science, 367(6485), 1444–1448. https://doi.org/10.1126/science.abb2762
   PubMed Web of Science ®Google Scholar
• Yang, J., Wang, W., Chen, Z., Lu, S., Yang, F., Bi, Z., Bao, L., Mo, F., Li, X., Huang, Y., Hong, W., Yang, Y., Zhao, Y., Ye, F., Lin, S., Deng, W., Chen, H., Lei, H., Zhang, Z., … Wei, X. (2020). A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature, 586(7830), 572–577. https://doi.org/10.1038/s41586-020-2599-8
   PubMed Web of Science ®Google Scholar
• Yin, J., Li, C., Ye, C., Ruan, Z., Liang, Y., Li, Y., Wu, J., & Luo, Z. (2022). Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. CSBJ, 20, 824–837. https://doi.org/10.1016/j.csbj.2022.01.026
   Google Scholar
• Zhang, Q., Xiang, R., Huo, S., Zhou, Y., Jiang, S., Wang, Q., & Yu, F. (2021). Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduction and Targeted Therapy, 6(1), 233. https://doi.org/10.1038/s41392-021-00653-w
   Web of Science ®Google Scholar